gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · CCCCHealthcareBiotechnology

C4 Therapeutics, Inc. (CCCC)

$3.12−2.80%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$3.06▲ 23.59% in range
Nov 3, 2025Low $1.71 · High $4.67Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

C4 Therapeutics closed at $3.12 on Nov 4, down 2.80%, 33.2% below its 52-week closing high. Volume of 2.0M shares was 0.68× its 20-day average (below normal).

Split-adjusted performance: +8.3% over one month, +6.5% over six months, +25.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $6.64M, up 2.8% from a year earlier, with a net margin of -355.9%.

Short interest was 42.7M shares at the Oct 15 settlement, up 5.8% from the prior report (43.4% of float, 16.9 days to cover).

Market cap$383.8M123.0M shares
Revenue · quarter$6.6M+2.8% YoY
Diluted EPS$-0.18—
P/E · TTM—P/S 11.0×
Net margin-355.9%Gross 100.0%
Dividend yieldNone
52-week range1.71 – 4.67−33.2% from high
Volume2.0M0.68× 20-day avg
Volatility · 60d64.0%Annualised
Short % of float43.4%17.0 days to cover
Net cash$253.7MCash $253.7M
Next earnings—Not scheduled
Split-adjusted performance
1W −8.1%1M +8.3%3M −14.3%6M +6.5%YTD +63.4%1Y +25.8%3Y +106.6%5Y −93.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum70
Revenue growth43
Net margin46
Value (low P/E)—
Size59

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short42.7M+5.8% vs prior
Days to cover17.0Settled Oct 15
% of float43.4%
Short vol. 10d48.1%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
CCCCC4 Therapeutics$3.12−2.80%+6.5%+2.8%−355.9%—$383.8M
ZURAZura Bio Limited$4.02+0.75%−17.8%———$387.2MCompare
SRZNSurrozen$31.65+5.08%−7.3%+408.6%640.8%—$372.0MCompare
TECXTectonic Therapeutic$20.30+6.95%−30.0%———$396.9MCompare
FENCFennec Pharmaceuticals$10.35−3.27%+44.2%+85.2%11.0%—$362.9MCompare
ALLOAllogene Therapeutics$1.19+6.25%−48.5%—−919.8%—$411.1MCompare
EDITEditas Medicine$2.72+4.62%−14.3%+232.3%−153.3%—$417.7MCompare
EIKNEikon Therapeutics$6.39+15.14%−35.9%———$346.1MCompare
XFORX4 Pharmaceuticals$3.24+2.21%−26.0%+346.3%−183.5%—$321.2MCompare

News about C4 Therapeutics

All news →
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual MeetingGlobeNewswire Inc. · Sep 25, 2026▲ PositiveC4 Therapeutics to Participate in Upcoming ConferencesGlobeNewswire Inc. · May 20, 2026Neutral

Quick answers

What does C4 Therapeutics do?
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases.
What is CCCC's market cap?
$383.84M, based on the Nov 4 close of $3.12.
Does C4 Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of CCCC is sold short?
42.7M shares, 43.4% of float, as of Oct 15, 2026.
What sector is CCCC in?
Healthcare, in the Biotechnology industry.

About C4 Therapeutics

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

HQ: Watertown, MA104 employeesListed Oct 2, 2020c4therapeutics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology